PMID- 21816022
OWN - NLM
STAT- MEDLINE
DCOM- 20111201
LR  - 20151119
IS  - 1756-185X (Electronic)
IS  - 1756-1841 (Linking)
VI  - 14
IP  - 3
DP  - 2011 Aug
TI  - Decrease of CD68 and MMP-3 expression in synovium by treatment of adalimumab for 
      rheumatoid arthritis.
PG  - 261-6
LID - 10.1111/j.1756-185X.2011.01643.x [doi]
AB  - AIMS: In order to investigate the histological change in the secondary 
      non-responder cases of adalimumab compared with methotrexate (MTX) treatment, we 
      performed immunohistochemical examination of synovial tissue by seven different 
      molecules to detect expression patterns of cytokines. METHODS: We histologically 
      assessed synovial tissues from five MTX-treated rheumatoid arthritis (RA) 
      patients as controls and five adalimumab plus MTX-treated RA patients after 
      arthroscopic synovectomy in the knee joints. The synovium of both groups were 
      assessed by hematoxylin and eosin (H&E) and analyzed the positive expression of 
      tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), matrix metalloproteinase-3 
      (MMP-3), B-cell precursor and mature B-cell transmembrane protein, CD20, 
      macrophage marker, CD68, vascular endothelial growth factor (VEGF), receptor 
      activator of nuclear (kappa) B ligand (RANKL) by immunohistochemical examination. 
      RESULTS: H&E staining showed the increase of vascular and cell proliferations in 
      the synovium of the RA patients who received adalimumab compared with the 
      controls. TNF-alpha, IL-6 and CD20 were not significantly different in either group. 
      On the other hand, MMP-3 and CD68 showed a significant decrease in the adalimumab 
      group compared with controls (P < 0.05). VEGF and RANKL were weakly positive in 
      both groups. CONCLUSION: Based on the histological analysis of synovium, the 
      effect attenuation of adalimumab may be involved in vascular and cell 
      proliferations; however, there was inhibition of the expression of CD68 and MMP-3 
      in synovium. These findings indicate CD68 and MMP-3 may have key roles in the 
      mechanism of efficacy of adalimumab.
CI  - (c) 2011 The Authors. International Journal of Rheumatic Diseases (c) 2011 Asia 
      Pacific League of Associations for Rheumatology and Blackwell Publishing Asia Pty 
      Ltd.
FAU - Kanbe, Katsuaki
AU  - Kanbe K
AD  - Department of Orthopaedic Surgery, Tokyo Women's Medical University, Medical 
      Center East, Tokyo, Japan. kanbeor@dnh.twmu.ac.jp
FAU - Chiba, Junji
AU  - Chiba J
FAU - Nakamura, Atsushi
AU  - Nakamura A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Int J Rheum Dis
JT  - International journal of rheumatic diseases
JID - 101474930
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antigens, CD)
RN  - 0 (Antigens, Differentiation, Myelomonocytic)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (CD68 antigen, human)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
RN  - FYS6T7F842 (Adalimumab)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - Adalimumab
MH  - Aged
MH  - Antibodies, Monoclonal, Humanized/*therapeutic use
MH  - Antigens, CD/*metabolism
MH  - Antigens, Differentiation, Myelomonocytic/*metabolism
MH  - Antirheumatic Agents/*therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy/metabolism/pathology
MH  - Cell Proliferation
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - Male
MH  - Matrix Metalloproteinase 3/*metabolism
MH  - Methotrexate/therapeutic use
MH  - Middle Aged
MH  - Synovial Membrane/blood supply/*drug effects/metabolism/pathology
EDAT- 2011/08/06 06:00
MHDA- 2011/12/13 00:00
CRDT- 2011/08/06 06:00
PHST- 2011/08/06 06:00 [entrez]
PHST- 2011/08/06 06:00 [pubmed]
PHST- 2011/12/13 00:00 [medline]
AID - 10.1111/j.1756-185X.2011.01643.x [doi]
PST - ppublish
SO  - Int J Rheum Dis. 2011 Aug;14(3):261-6. doi: 10.1111/j.1756-185X.2011.01643.x.